Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1984 Dec;46(3):673–676. doi: 10.1128/iai.46.3.673-676.1984

Human opsonins to meningococci after vaccination.

A Halstensen, B Haneberg, L O Frøholm, V Lehmann, C E Frasch, C O Solberg
PMCID: PMC261595  PMID: 6437988

Abstract

Two groups of volunteers were immunized with either a serogroup A plus C meningococcal polysaccharide vaccine or a combined serogroup B polysaccharide-serotype 2 protein vaccine. Serum opsonin responses were measured by chemiluminescence of polymorphonuclear leukocytes exposed to opsonized live meningococci. Two of the six volunteers immunized with the A plus C vaccine had an increase in serum opsonins to group A meningococci, four responded to group C meningococci, and none to group B meningococci. Five other volunteers who were immunized with the combined group B polysaccharide-serotype 2 protein vaccine responded with an increase in serum opsonins to group B meningococci of two different protein serotypes, as well as to a group C-serotype 2 meningococcal strain. Although no booster effect was observed after a second dose of the combined vaccine, both the polysaccharide and the protein components appear to be able to stimulate an opsonin response.

Full text

PDF
673

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ashton F. E., Ryan J. A., Diena B. B., Frasch C. E. Immunogenic and protective properties of meningococcal serotype 2a protein in the hen-embryo model. J Med Microbiol. 1983 Nov;16(4):443–457. doi: 10.1099/00222615-16-4-443. [DOI] [PubMed] [Google Scholar]
  2. Craven D. E., Frasch C. E. Protection against group B meningococcal disease: evaluation of serotype 2 protein vaccines in a mouse bacteremia model. Infect Immun. 1979 Oct;26(1):110–117. doi: 10.1128/iai.26.1.110-117.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Craven D. E., Shen K. T., Frasch C. E. Natural bactericidal activity of human serum against Neisseria meningitidis isolates of different serogroups and serotypes. Infect Immun. 1982 Jul;37(1):132–137. doi: 10.1128/iai.37.1.132-137.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Frasch C. E., Parkes L., McNelis R. M., Gotschlich E. C. Protection against group B meningococcal disease. I. Comparison of group-specific and type-specific protection in the chick embryo model. J Exp Med. 1976 Aug 1;144(2):319–329. doi: 10.1084/jem.144.2.319. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Frasch C. E., Peppler M. S. Protection against group B Neisseria meningitidis disease: preparation of soluble protein and protein-polysaccharide immunogens. Infect Immun. 1982 Jul;37(1):271–280. doi: 10.1128/iai.37.1.271-280.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Frasch C. E., Robbins J. D. Protection against group B meningococcal disease. III. Immunogenicity of serotype 2 vaccines and specificity of protection in a guinea pig model. J Exp Med. 1978 Mar 1;147(3):629–644. doi: 10.1084/jem.147.3.629. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Frøholm L. O., Berdal B. P., Bøvre K., Gaustad P., Harboe A., Holten E., Høiby E. A., Lystad A., Omland T., Frasch C. E. Meningococcal group B vaccine trial in Norway 1981--1982. Preliminary report of results available November 1982. NIPH Ann. 1983 Dec;6(2):133–138. [PubMed] [Google Scholar]
  8. Glode M. P., Lewin E. B., Sutton A., Le C. T., Gotschlich E. C., Robbins J. B. Comparative immunogenicity of vaccines prepared from capsular polysaccharides of group C Neisseria meningitidis O-acetyl-positive and O-acetyl-negative variants and Escherichia coli K92 in adult volunteers. J Infect Dis. 1979 Jan;139(1):52–59. doi: 10.1093/infdis/139.1.52. [DOI] [PubMed] [Google Scholar]
  9. Gold R., Artenstein M. S. Meningococcal infections. 2. Field trial of group C meningococcal polysaccharide vaccine in 1969-70. Bull World Health Organ. 1971;45(3):279–282. [PMC free article] [PubMed] [Google Scholar]
  10. Gotschlich E. C., Goldschneider I., Artenstein M. S. Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers. J Exp Med. 1969 Jun 1;129(6):1367–1384. doi: 10.1084/jem.129.6.1367. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Lehmann V., Solberg C. O. Group B meningococcal opsonins in serum measured by polymorphonuclear leukocyte chemiluminescence. Acta Pathol Microbiol Scand C. 1980 Aug;88(4):227–231. doi: 10.1111/j.1699-0463.1980.tb00098.x. [DOI] [PubMed] [Google Scholar]
  12. Peltola H., Mäkelä H., Käyhty H., Jousimies H., Herva E., Hällström K., Sivonen A., Renkonen O. V., Pettay O., Karanko V. Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age. N Engl J Med. 1977 Sep 29;297(13):686–691. doi: 10.1056/NEJM197709292971302. [DOI] [PubMed] [Google Scholar]
  13. Roberts R. B. The interaction in vitro between group B meningococci and rabbit polymorphonuclear leukocytes. Demonstration of type specific opsonins and bactericidins. J Exp Med. 1967 Nov 1;126(5):795–818. doi: 10.1084/jem.126.5.795. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Roberts R. B. The relationship between group A and group C meningococcal polysaccharides and serum opsonins in man. J Exp Med. 1970 Mar 1;131(3):499–513. doi: 10.1084/jem.131.3.499. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Wyle F. A., Artenstein M. S., Brandt B. L., Tramont E. C., Kasper D. L., Altieri P. L., Berman S. L., Lowenthal J. P. Immunologic response of man to group B meningococcal polysaccharide vaccines. J Infect Dis. 1972 Nov;126(5):514–521. doi: 10.1093/infdis/126.5.514. [DOI] [PubMed] [Google Scholar]
  16. Zollinger W. D., Mandrell R. E., Altieri P., Berman S., Lowenthal J., Artenstein M. S. Safety and immunogenicity of a Neisseria meningitidis type 2 protein vaccine in animals and humans. J Infect Dis. 1978 Jun;137(6):728–739. doi: 10.1093/infdis/137.6.728. [DOI] [PubMed] [Google Scholar]
  17. Zollinger W. D., Mandrell R. E., Griffiss J. M., Altieri P., Berman S. Complex of meningococcal group B polysaccharide and type 2 outer membrane protein immunogenic in man. J Clin Invest. 1979 May;63(5):836–848. doi: 10.1172/JCI109383. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Zollinger W. D., Mandrell R. E. Importance of complement source in bactericidal activity of human antibody and murine monoclonal antibody to meningococcal group B polysaccharide. Infect Immun. 1983 Apr;40(1):257–264. doi: 10.1128/iai.40.1.257-264.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES